2013
DOI: 10.1517/17425255.2013.777428
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease

Abstract: SUMMARYIntroduction : People with chronic kidney disease (CKD) of stages 3-5 (creatinine clearance < 60 ml/min) represent 25-30% of patients with type 2 diabetes (T2DM), but the problem is underrecognized or neglected in clinical practice. However, most oral antidiabetic agents have limitations in case of renal impairment, either because they require a dose adjustment or because they are contraindicated for safety reasons. Expert Opinion : Because of potential important PK interferences and for safety reasons,… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

3
62
0
2

Year Published

2013
2013
2023
2023

Publication Types

Select...
5
3

Relationship

1
7

Authors

Journals

citations
Cited by 81 publications
(67 citation statements)
references
References 163 publications
(149 reference statements)
3
62
0
2
Order By: Relevance
“…Thus, caution is required, especially in patients with severe HI. In contrast to patients with CLD, in patients with chronic kidney disease, several studies have been published, which combine not only PK analysis after a single administration but also clinical efficacy/safety data after chronic administration up to 1 year in T2DM patients [22] . Such long-term clinical studies are not available in diabetic patients with CLD.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Thus, caution is required, especially in patients with severe HI. In contrast to patients with CLD, in patients with chronic kidney disease, several studies have been published, which combine not only PK analysis after a single administration but also clinical efficacy/safety data after chronic administration up to 1 year in T2DM patients [22] . Such long-term clinical studies are not available in diabetic patients with CLD.…”
Section: Discussionmentioning
confidence: 99%
“…Therefore, renal function should be carefully monitored in all patients with cirrhosis and selection of antidiabetic pharmacotherapy should also take into account the possibility of associated renal impairment in such patients [22] . This is of major importance because the dosage of DPP-4 inhibitors (except linagliptin) should be adjusted to the glomerular filtration rate and there are restrictions regarding the use of GLP-1 receptor agonists in presence of moderate to severe kidney insufficiency [14,22] .…”
Section: Evaluation Of Severity Of Himentioning
confidence: 99%
See 1 more Smart Citation
“…Caution is thus recommended in the interpretation of the available data, which could not be automatically extrapolated to patients with T2DM, especially when comorbidities are present such as chronic kidney disease (CKD) [19,25] or hepatic impairment [19] .…”
Section: Literature Searchmentioning
confidence: 99%
“…In general, the subjective tolerance profile was slightly better with DPP-4 inhibitors than with SGLT-2 inhibitors. No comparative study concerned patients with renal impairment 10 Most of these trials were rather short-term (12-24 weeks) so that it is difficult to conclude on the long-term efficacy of each compound. Durability of the glucose-lowering effect is a crucial issue because T2DM is an evolving disease and progressive metabolic deterioration is commonly observed with all available glucose-lowering agents.…”
mentioning
confidence: 99%